Blood loss kills more than 25,000 Americans every year before they reach a hospital. The treatment already exists. It just can't get there on time.
The Defense Advanced Research Projects Agency (DARPA) has put $46 million behind a whole-blood program with ErythroMer at its core, and a follow-on effort now targets FDA authorization for a fieldable system by 2029.
KaloCyte, a Baltimore startup with two granted patents, is running investigational-new-drug (IND) enabling studies and still seeking Series A money for a $7 billion US market.
The problem is older than most ambulance services. Donated red blood cells spoil after about a month, need refrigeration everywhere they go, and come type-specific when a bleeding patient rarely has time to be typed. So the people who bleed out the fastest bleed out without a transfusion.
Fewer than a handful of companies have ever built an actual workaround. All of them, so far, have failed in front of the FDA.
How a blood product dies
The graveyard starts in the 1980s. Fluosol, a perfluorocarbon emulsion, won approval in 1989 and was pulled a few years later. Hemopure, made from bovine hemoglobin, outlived some of its rivals but never recovered commercially. PolyHeme, pitched as a universal substitute for civilian trauma, ran a large US trial at the turn of the century and then disappeared too.
The pattern behind those failures is consistent. Free hemoglobin outside a red blood cell binds nitric oxide and scrubs it from the blood vessel wall, which drives vasoconstriction, high blood pressure, kidney strain, and in one halted 2002 Phase III study, a spike in strokes. A metareview in JAMA tied the whole class to excess heart attack risk, and that became the tombstone for first-generation hemoglobin-based oxygen carriers.
The lesson defenders of the field repeat today: the problem was never oxygen. It was architecture.
"We've imitated the mechanism in normal red cells for optimizing oxygen transport from lungs to tissue. The principal idea is not to interfere with the signaling between red blood cells and blood vessels."— Allan Doctor, co-founder and CSO, KaloCyte
What ErythroMer actually is
KaloCyte was spun out of the University of Maryland in 2016, built around a different bet: don't free the hemoglobin, rehouse it. ErythroMer is a lipid nanoparticle that packs a high payload of human hemoglobin, then wraps it in a soft shell with a pH-responsive small molecule that controls how eagerly oxygen is captured in the lungs and released in working tissue.
The particles are roughly 50 times smaller than a natural red blood cell. The company says the small size and the bio-inspired regulator are the point: the product corrects the two failures of everything before it, oxygen delivery and safety. In animal models so far, KaloCyte reports minimal toxicity and efficient oxygen transfer.
Shelf life is the commercial weapon. ErythroMer is freeze-dried into a powder, packaged in a dual-chamber IV bag, and reconstitutes with sterile water in under a minute at room temperature. No cold chain, no blood typing, no cross-match. A first responder carries it, mixes it, and infuses a universal unit on scene.
Two patents now anchor the moat. A self-assembling oxygen carrier composition granted in March 2025, and a method for removing synthetic nanoparticles from blood granted in December 2024.
"We are currently working with CBOTH's academic researchers and a number of other organizations on a significant research project funded by the Defense Advanced Research Projects Agency (DARPA) to develop deployable, shelf-stable, universal whole blood substitute as a hemorrhage countermeasure to sustain injured warfighters in austere, pre-hospital settings. ErythroMer will be a core component of this product."— Elaine Haynes, President and CEO, KaloCyte
Why the Pentagon runs the clock
The strategic buyer was obvious from the start. Blood loss is the leading cause of preventable death in combat and trauma alike, and the military cannot refrigerate blood across every landing zone. DARPA answered with FSHARP, a $46 million program run through the University of Maryland, with ErythroMer as the core oxygen-carrying component and researchers at Pittsburgh's military medicine center building out the rest. The bet includes the hard engineering: keep a full blood analog stable up to six months without cold chain, and make it in the quantities the Department of Defense actually needs.
That program has been crossing its checkpoints. In May 2026 DARPA announced the next step, RAPIID, which is explicitly working backwards from regulatory reality: a fieldable, FDA-authorized blood analog system by 2029. In July 2026, the consortium published work on L-TOF, an assay that directly compares oxygen delivery potency between different blood products, a kind of quality yardstick the field had never had.
None of that makes ErythroMer a drug yet. KaloCyte is pre-clinical, running the IND-enabling toxicology and pharmacology studies that would qualify it to file an Investigational New Drug application. So far the company has drawn more than $19 million in DARPA, NIH, and DoD grants and over $8 million in investor funding. It was accepted into Blue Knight, the BARDA and Johnson & Johnson incubator, in January 2025, and signed an exclusive license with Chrysea in October 2025 for biosynthetic hemoglobin production, a move that decouples supply from donor blood entirely.
Here is the market math an investor should check. KaloCyte puts the US opportunity at about $7 billion, priced near the fully-loaded cost of a unit of donor blood. The demand signal is structural: roughly 47 million Americans live more than an hour from a trauma center, most ambulances do not stock blood, and each minute of delay raises mortality by about five percent.
The honest counterweight is that the last generation of blood substitutes died precisely at this stage, between the preclinical promise and the Phase III swamp. A nano-carrier that works in rabbits is a thesis, not a product. The distinct difference here is the buyer architecture: DARPA is paying for the outcome and has laid out a dated path to authorization, which changes the risk profile for equity in a way a purely commercial launch never did.
"There's nothing that has a bigger impact on survival than prehospital blood. Nothing. And yet the major impediment is not logistics — we've worked through that. It's not how to store the blood. It's reimbursement."— Col. (Ret.) John B. Holcomb, trauma surgeon, speaking on the broader field
Reimbursement is the slow graveyard where every earlier substitute met its end. What has changed is that the largest single buyer in the world has decided it cannot wait for donor blood, and it is writing the check that moves a Baltimore lab from powder to approval. If RAPIID holds to 2029, the freezerless blood unit becomes a stocked shelf item in both an Army aid station and a rural county ambulance. That is the moment the 25,000 becomes a manageable number.
